ALX Oncology Holdings Inc (NAS:ALXO)
$ 2 +0.020 (+1.01%) Market Cap: 276.55 Mil Enterprise Value: 148.03 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

Q1 2026 ALX Oncology Holdings Inc Earnings Call Transcript

May 08, 2026 / 12:30PM GMT
Release Date Price: $2.08 (+11.23%)
Operator

Greetings, and welcome to the ALX Oncology first quarter 2026 financial results conference and webcast. At this time, all participants are in a listen-only mode. (Operator Instructions) Please note, this conference is being recorded.

I will now turn the conference over to your host, Jason Letrmann, CEO. Please go ahead, sir.

Jason Lettmann
ALX Oncology Holdings Inc - Chief Executive Officer, Director

Thanks, everyone, and welcome to our Q1 2026 results. I really appreciate you all spending time with us this morning and are looking forward to sharing these updates with you. On slide 2, and before we start our presentation of housekeeping, here are our forward-looking statements for your review. On slide 3, here's the agenda and plan for today.

We're going to be providing an update on our key accomplishments in the first quarter of 2026. Most notably, we are very excited to share with you the dataset that was presented yesterday in Munich at ESMO Breast 2026 from the analysis of our trial evaluating evorpercept and zanidatimab, which clearly

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot